{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-006999","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.686790+00:00","generated_at":"2026-06-18T07:30:59.602710+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ALX Oncology reports Q4 net loss $30.7M; cash $282.9M; clinical milestones ahead","bullets":["Q4 2022 GAAP net loss $30.7M ($0.75/sh) vs $28.4M ($0.70/sh) in Q4 2021.","Full year 2022 GAAP net loss $123.5M ($3.03/sh) vs $83.5M ($2.07/sh) in 2021.","Cash & investments $282.9M; $100M loan facility (drew $10M); runway through mid-2025.","Key milestones: ASPEN-06 (gastric) and ASPEN-02 (MDS) data H2 2023; ASPEN-07 (UC) dosed Feb 2023.","Board strengthened with Scott Garland; IND for ALTA-002 (Tallac) expected H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-006999","json":"https://secwatch.observer/filing/0000950170-23-006999.json","markdown":"https://secwatch.observer/filing/0000950170-23-006999.md","text":"https://secwatch.observer/filing/0000950170-23-006999.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000095017023006999/0000950170-23-006999-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000095017023006999/alxo-20230309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T07:30:59.602710+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ae17178b13ed838742645b470af0f3fa8ecbc3db","claim":"ALX ONCOLOGY HOLDINGS INC reported financial results for fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"ALX Oncology Holdings Inc. (the \"Company\"), issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017023006999/0000950170-23-006999-index.htm","confidence":0.4,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}